Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin +/- Endocrine Therapy in HR+/HER2- mBC (REVERT)
NCT03795012Phase 2Terminated
- Sponsor
- MEDSIR
- Start
- Apr 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eribulin in breast cancer (2 arms), sponsored by MEDSIR. Primary endpoint: Overall Response Rate up to 27 months. Started Apr 2019; status: terminated.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03795012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795012.